Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3324/haematol.12638 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling urinary extracellular vesicle mRNA signature for early diagnosis and prognosis of bladder cancer.
Theranostics
January 2025
State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Molecular Recognition and Biosensing, Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tianjin 300071, China.
Bladder cancer (BC) ranks as one of the most prevalent cancers. Its early diagnosis is clinically essential but remains challenging due to the lack of reliable biomarkers. Extracellular vesicles (EVs) carry abundant biological cargoes from parental cells, rendering them as promising cancer biomarkers.
View Article and Find Full Text PDFComprehensive analysis of tumor immune-related gene signature for predicting prognosis, immunotherapy, and drug sensitivity in bladder urothelial carcinoma.
Transl Cancer Res
December 2024
Department of Urology, Affiliated Hospital of Chifeng University, Chifeng, China.
Background: Bladder urothelial carcinoma (BLCA) is globally recognized as a prevalent malignancy. Its treatment remains challenging due to the extensive morbidity, high mortality rates, and compromised quality of life from postoperative complications and the lack of specific molecular targets. Our aim was to establish a prognostic model to evaluate the prognostic significance, assess immunotherapy responses, and determine drug susceptibility in patients with BLCA.
View Article and Find Full Text PDFMulitDeepsurv: survival analysis of gastric cancer based on deep learning multimodal fusion models.
Biomed Opt Express
January 2025
Computer Engineering Department, Taiyuan Institute of Technology, Taiyuan 030008, China.
Gastric cancer is a leading cause of cancer-related deaths globally. As mortality rates continue to rise, predicting cancer survival using multimodal data-including histopathological images, genomic data, and clinical information-has become increasingly crucial. However, extracting effective predictive features from this complex data has posed challenges for survival analysis due to the high dimensionality and heterogeneity of histopathology images and genomic data.
View Article and Find Full Text PDFHigh expression of RBM15 is associated with better prognosis in esophageal squamous cell carcinoma.
J Gastrointest Oncol
December 2024
Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
Background: Esophageal squamous cell carcinoma (ESCC) is a highly prevalent and malignant form of esophageal tumor associated with high rates of patient mortality for which there remains a persistent lack of effective targets for therapeutic interventional efforts. This study was developed with the goal of exploring the expression and functional role of RBM15 in ESCC.
Methods: This study was developed with the goal of exploring the expression and functional role of RBM15 in ESCC.
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis.
Leukemia
January 2025
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Expression of CD2, CD25 and/or CD30 in extracutaneous mast cells (MC) is a minor diagnostic criterion for systemic mastocytosis (SM) in the classification of the World Health Organization and International Consensus Classification. So far, it remains unknown whether expression of these antigens on MC is of prognostic significance in SM. We performed a retrospective multi-center study of patients with SM using the data set of the registry of the European Competence Network on Mastocytosis, including 5034 patients with various MC disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!